Physician profile
Jerry Miles
NPI 1710914973
$58,493.41
in general payments reported to CMS, 2019-2025
35 companies · $5,278 in 2025
The $5,278 reported for 2025 was more than what 96% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,239 · 2020: $7,846 · 2021: $12K · 2022: $23K · 2023: $2,308 · 2024: $4,319 · 2025: $5,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,000 · Food and Beverage: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,000.00 |
| Food and Beverage | $2,904.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bone Support INC. | $26,631.52 | 2019-2025 | Ceramentbone Void Filler, Cerament G |
| Triad Life Sciences INC. | $18,568.75 | 2022 | |
| Dne LLC | $7,379.80 | 2020-2021 | |
| Stryker Corporation | $3,618.11 | 2019-2025 | Augment Injectable, Hoffmann, Salvation |
| Sanara Medtech INC. | $194.13 | 2021 | |
| Organogenesis INC. | $191.90 | 2020-2021 | |
| Horizon Therapeutics Plc | $150.22 | 2021-2023 | Krystexxa |
| Zimmer Biomet Holdings, INC. | $149.61 | 2019 | |
| Osiris Therapeutics INC. | $133.95 | 2019 | |
| Trilliant Surgical LLC. | $131.54 | 2019 | |
| Imbed Biosciences INC. | $131.44 | 2022 | |
| Medtronic, INC. | $116.19 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Comsort, INC | $100.00 | 2019 | |
| Smith+Nephew, INC. | $99.86 | 2019-2025 | Grafix Pl, Renasys Go V2 Home |
| Nevro Corp. | $92.28 | 2022-2024 | Senza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vaporox, INC. | $91.73 | 2024 | Vht-200 Wound Treatment System |
| Medinc of Texas | $81.15 | 2025 | |
| Reddress USA, INC. | $80.06 | 2024 | |
| Dynasplint Systems INC. | $67.41 | 2020-2021 | |
| Wound Management Technologies, INC | $56.54 | 2019 | |
| Treace Medical Concepts, INC. | $48.15 | 2022-2023 | |
| Sebela Pharmaceuticals INC. | $43.27 | 2021-2022 | |
| Tactile Systems Technology INC | $42.08 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Averitas Pharma INC. | $40.43 | 2023-2024 | Qutenza |
| Bioventus LLC | $33.25 | 2019-2021 | |
| Kerecis Limited | $29.64 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Arthrosurface Incorporated | $25.96 | 2019 | |
| Kci USA, INC. | $24.76 | 2019 | |
| Wright Medical Technology, INC. | $23.24 | 2019 | |
| Paratek Pharmaceuticals, INC. | $23.17 | 2023 | Nuzyra |
| Medline Industries Lp | $22.65 | 2021 | |
| Inari Medical, INC. | $20.29 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Innovation Technologies INC | $19.32 | 2024 | Irrisept |
| Next Science LLC | $18.59 | 2023 | Blastx, Xperience, Surgx |
| Anika Therapeutics, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.